Oxigene

A second-generation VDA focused on hematologic malignancies; initiated Phase 1b/2 trials in 2015. Myopic Macular Degeneration

The shift to Mateon Therapeutics reflected a broader focus on "Vascular Targeted Therapy" (VTT), which combines VDAs with anti-angiogenic agents to trap and destroy tumor cores while preventing new vessel growth. Historical Acquisitions: Oxigene

OXiGENE, Inc. was a clinical-stage biopharmaceutical company that rebranded as in June 2016. The company specialized in developing Vascular Disrupting Agents (VDAs) designed to selectively dismantle blood vessels that sustain solid tumors and contribute to visual impairment. Corporate Evolution Lead candidate; received and Orphan Drug designations for

Despite promising science, the company faced periodic financial restructurings, including a significant workforce reduction in 2011 to conserve resources for early-stage programs. ZYBRESTAT and OXi4503

Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503

In 2009, OXiGENE re-acquired full rights to its lead candidates, ZYBRESTAT and OXi4503, from Symphony ViDA. Lead Pharmaceutical Pipeline